Journal Article

DKFZ-2022-01956

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.

Möhrmann, L. (First author)DKFZ* ; Huang, H. J. ; Hong, D. S. ; Tsimberidou, A. M. ; Fu, S. ; Piha-Paul, S. A. ; Subbiah, V. ; Karp, D. D. ; Naing, A. ; Krug, A. ; Enderle, D. ; Priewasser, T. ; Noerholm, M. ; Eitan, E. ; Coticchia, C. ; Stoll, G. ; Jordan, L.-M. ; Eng, C. ; Kopetz, E. S. ; Skog, J. ; Meric-Bernstam, F. ; Janku, F.

2018
AACR Philadelphia, Pa. [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1158/1078-0432.CCR-17-2007

Abstract: Purpose: Blood-based liquid biopsies offer easy access to genomic material for molecular diagnostics in cancer. Commonly used cell-free DNA (cfDNA) originates from dying cells. Exosomal nucleic acids (exoNAs) originate from living cells, which can better reflect underlying cancer biology.Experimental Design: Next-generation sequencing (NGS) was used to test exoNA, and droplet digital PCR (ddPCR) and BEAMing PCR were used to test cfDNA for BRAFV600, KRASG12/G13, and EGFRexon19del/L858R mutations in 43 patients with progressing advanced cancers. Results were compared with clinical testing of archival tumor tissue and clinical outcomes.Results: Forty-one patients had BRAF, KRAS, or EGFR mutations in tumor tissue. These mutations were detected by NGS in 95% of plasma exoNA samples, by ddPCR in 92% of cfDNA samples, and by BEAMing in 97% cfDNA samples. NGS of exoNA did not detect any mutations not present in tumor, whereas ddPCR and BEAMing detected one and two such mutations, respectively. Compared with patients with high exoNA mutation allelic frequency (MAF), patients with low MAF had longer median survival (11.8 vs. 5.9 months; P = 0.006) and time to treatment failure (7.4 vs. 2.3 months; P = 0.009). A low amount of exoNA was associated with partial response and stable disease ≥6 months (P = 0.006).Conclusions: NGS of plasma exoNA for common BRAF, KRAS, and EGFR mutations has high sensitivity compared with clinical testing of archival tumor and testing of plasma cfDNA. Low exoNA MAF is an independent prognostic factor for longer survival. Clin Cancer Res; 24(1); 181-8. ©2017 AACR.

Keyword(s): Adult (MeSH) ; Aged (MeSH) ; Biomarkers, Tumor (MeSH) ; Cell-Free Nucleic Acids (MeSH) ; ErbB Receptors: blood (MeSH) ; ErbB Receptors: genetics (MeSH) ; Exosomes (MeSH) ; Female (MeSH) ; Genetic Testing (MeSH) ; Humans (MeSH) ; Liquid Biopsy: methods (MeSH) ; Male (MeSH) ; Middle Aged (MeSH) ; Mutation (MeSH) ; Neoplasm Grading (MeSH) ; Neoplasm Staging (MeSH) ; Neoplasms: blood (MeSH) ; Neoplasms: diagnosis (MeSH) ; Neoplasms: mortality (MeSH) ; Patient Outcome Assessment (MeSH) ; Proto-Oncogene Proteins B-raf: blood (MeSH) ; Proto-Oncogene Proteins B-raf: genetics (MeSH) ; Proto-Oncogene Proteins p21(ras): blood (MeSH) ; Proto-Oncogene Proteins p21(ras): genetics (MeSH) ; Survival Analysis (MeSH) ; Biomarkers, Tumor ; Cell-Free Nucleic Acids ; KRAS protein, human ; EGFR protein, human ; ErbB Receptors ; BRAF protein, human ; Proto-Oncogene Proteins B-raf ; Proto-Oncogene Proteins p21(ras)

Note: POF Topic: 317

---

Contributing Institute(s):

1. Translationale Onkologie (G100)

Research Program(s):

1. 317 - Translational cancer research (POF3-317) (POF3-317)

Appears in the scientific report 2018

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---